Inmune Bio Stock Price on December 20, 2024
| INMB Stock | USD 4.42 0.15 3.28% |
Below is the normalized historical share price chart for INmune Bio extending back to February 04, 2019. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of INmune Bio stands at 4.42, as last reported on the 21st of December, with the highest price reaching 4.79 and the lowest price hitting 4.36 during the day.
If you're considering investing in INmune Stock, it is important to understand the factors that can impact its price. INmune Bio holds Efficiency (Sharpe) Ratio of -0.0355, which attests that the entity had a -0.0355% return per unit of risk over the last 3 months. INmune Bio exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out INmune Bio's Risk Adjusted Performance of (0.02), standard deviation of 4.24, and Market Risk Adjusted Performance of 0.528 to validate the risk estimate we provide.
At present, INmune Bio's Common Stock is projected to increase significantly based on the last few years of reporting. The current year's Capital Stock is expected to grow to about 857.9 K, whereas Total Stockholder Equity is forecasted to decline to about 33.6 M. . At present, INmune Bio's Price Book Value Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 5.57, whereas Price To Sales Ratio is forecasted to decline to 1,241. INmune Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 4th of February 2019 | 200 Day MA 7.8231 | 50 Day MA 5.2847 | Beta 1.852 |
INmune |
Sharpe Ratio = -0.0355
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INMB |
Estimated Market Risk
| 4.29 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average INmune Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of INmune Bio by adding INmune Bio to a well-diversified portfolio.
Price Book 2.5111 | Enterprise Value Ebitda (5.31) | Price Sales 2.3 K | Shares Float 14.3 M | Wall Street Target Price 19.8333 |
Related Headline
AN2 Therapeutics Headline on 20th of December 2024
WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Prod... by finance.yahoo.com
WillowWood, a global leader in prosthetic solutions, is proud to announce its receipt of the prestigious Gold Anthem Award Honor in the Product and Innovation category for its 2024 rebrand. The award recognizes the transformative collaboration with DD.NYC that has redefined WillowWoods visual identity, emphasizing its mission to improve mobility, push the forefront of the prosthetic industry, and enhance the quality of life for individuals worldwide.
INmune Bio Valuation on December 20, 2024
It is possible to determine the worth of INmune Bio on a given historical date. On December 20, 2024 INmune was worth 4.68 at the beginning of the trading date compared to the closed value of 4.42. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of INmune Bio stock. Still, in general, we apply an absolute valuation method to find INmune Bio's value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of INmune Bio where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against INmune Bio's related companies.
| Open | High | Low | Close | Volume | |
| 4.68 | 4.79 | 4.36 | 4.42 | 242,846 | |
12/21/2024 | 4.68 | 4.79 | 4.36 | 4.42 | 0.00 |
| Backtest INmune Bio | | | INmune Bio History | | | INmune Bio Valuation | Previous |
INmune Bio Trading Date Momentum on December 20, 2024
| On December 21 2024 INmune Bio was traded for 4.42 at the closing time. The top price for the day was 4.79 and the lowest listed price was 4.36 . There was no trading activity during the period 0.0. Lack of trading volume on December 21, 2024 did not cause price change. The trading delta at closing time against the current closing price is 5.88% . |
INmune Bio Fundamentals Correlations and Trends
By evaluating INmune Bio's financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among INmune Bio's main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. INmune financial account trend analysis is a perfect complement when working with valuation or volatility modules.About INmune Bio Stock history
INmune Bio investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for INmune is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in INmune Bio will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing INmune Bio stock prices may prove useful in developing a viable investing in INmune Bio
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 18 M | 14.8 M | |
| Net Loss | -24.6 M | -23.3 M |
INmune Bio Quarterly Net Working Capital |
|
INmune Bio Stock Technical Analysis
INmune Bio technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Price Boundaries
INmune Bio Period Price Range
Low | December 21, 2024
| High |
0.00 | 0.00 |
INmune Bio cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
INmune Bio December 21, 2024 Market Strength
Market strength indicators help investors to evaluate how INmune Bio stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading INmune Bio shares will generate the highest return on investment. By undertsting and applying INmune Bio stock market strength indicators, traders can identify INmune Bio entry and exit signals to maximize returns
INmune Bio Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for INmune Bio's price direction in advance. Along with the technical and fundamental analysis of INmune Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of INmune to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.16) | |||
| Total Risk Alpha | (0.28) | |||
| Treynor Ratio | 0.518 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |